The last time markets watched a category go from grey-market chemistry set to institutional asset class, it was crypto. The setup was familiar: heavy retail adoption, a sprawling offshore supply chain, an aggressive Biden-era enforcement posture, and a single regulatory event — the spot Bitcoin ETF approvals — that re-priced everything overnight. That arc may be repeating itself in an unlikely place: peptides.